Visiongain Report Researches Growth Opportunities Within the $138bn Pharmaceutical Contract Manufacturing Market
- Pharmaceutical Contract Manufacturing Market 2019-2029
- Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages
LONDON, Oct. 21, 2019 /PRNewswire/ -- The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 5.7% in the first half of the forecast period. The API Manufacturing submarket held 67% of the market in 2018. Visiongain estimated that the pharmaceutical contract manufacturing market will reach $138bn in 2024.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 231-page report you will receive 73 tables and 55 figures– all unavailable elsewhere.
The 231-page Visiongain report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
To request sample pages from this report please contact Sara Peerun at email@example.com or refer to our website: https://www.visiongain.com/report/pharmaceutical-contract-manufacturing-market-2019-2029/#download_sampe_div
• Global Pharmaceutical Contract Manufacturing Market forecasts from 2019-2029
• Submarket forecasts at world level, from 2019-2029:
• Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
• Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types
• Other applications of outsourced production – other related services
• Revenue forecasts from 2019-2029, for these regional and national markets:
• The US
• EU5: Germany, France, the UK, Italy and Spain
• BRIC: Brazil, Russia, India, China
• South Korea
• Assessment of selected leading companies that hold major market shares in the pharmaceutical contract manufacturing industry
• Qualitative Analysis from a CMO Perspective
• Qualitative Analysis from a Client Perspective
• Key questions answered by this report:
• What is the current size of the total global pharmaceutical contract manufacturing market?
• How much will this market be worth from 2018 to 2029?
• How is the pharmaceutical contract manufacturing market evolving?
• What is driving and restraining the pharmaceutical contract manufacturing market?
• What are the market shares of each segment of the overall pharmaceutical contract manufacturing market currently and how will these change to 2029?
• What are the main submarkets and how much revenue will each pharmaceutical contract manufacturing submarket account for over the next 10 years to 2029 and why?
• How will the market shares for each pharmaceutical contract manufacturing submarket develop from 2018 to 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve to 2029?
• What are the largest national markets for pharmaceutical contract manufacturing? What is the current status and how will it develop over the next ten years? What are their forecasts for 2019-2029?
• Who are the most prominent companies, and what are their activities and outlooks?
• What are the main trends that will affect the pharmaceutical contract manufacturing market between 2018 and 2029?
To request a report overview of this report please contact Sara Peerun at firstname.lastname@example.org or refer to our website: https://www.visiongain.com/report/pharmaceutical-contract-manufacturing-market-2019-2029/
Did you know that we also offer a report add-on service? Email email@example.com to discuss any customized research needs you may have.
Companies covered in the report include:
Ajinomoto Althea Inc
AMRI (Albany Molecular Research Inc)
API Corporation (APIC)
Banner Life Sciences
Baring Private Equity Asia
Bausch & Lomb
Ben Venue Laboratories
BioIndustry Association (BIA)
Boehringer Ingelheim BioXcellence
Bristol-Myers Squibb Company
Cambridge Major Laboratories
Catalent Pharma Solutions
Cell Therapy Catapult
Chemisch-Pharmazeutisches Laboratorium Ravensburg
China FDA (CFDA)
DPx Fine Chemicals
DPx Holdings B.V.
Dr. Reddy's Laboratories
DSP (DSM Sinochem Pharmaceuticals)
FUJIFILM Diosynth Biotechnologies,
Gallus Biopharmaceutical, LLC.
Indian Pharmaceutical Alliance
Johnson & Johnson
Knowledge Transfer Network (KTN)
Merck & Co.
Mitsui & Co
Orchid Chemicals & Pharmaceuticals
Piramal Pharma Solutions
Stevenage Bioscience Catalyst
Thermo Fisher Scientific
Valerion Therapeutics, LLC.
Vetter Pharma-Fertigung GmbH
Vivante GMP Solutions
West Pharmaceutical Services
Zhangjiang Biotech & Pharmaceutical Base Company
Zhejiang Jiang Yuan Tang Biotechnology
List or Organizations Mentioned in the Report
Agência Nacional de Vigilância Sanitária (ANVISA)
Asociación Española de Fabricantes de Productos de Química Fina (AFAQUIM)
Associação Brasileira da Indústria Farmoquímica e de Insumos Farmacêuticos (ABIQUIFI)
Association of British Pharmaceutical Industry (ABPI)
Central Drugs Standard Control Organization (CDSCO)
Department of Health and Family Welfare
Development and Reform Commission (NDRC)
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Indian Drug Manufacturer's Association (IDMA)
International Society of Pharmaceutical Engineering (IPSE)
Korea Food and Drug Administration (KFDA)
Korea Pharmaceutical Manufacturer's Association (KPMA)
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicines Manufacturing Industry Partnership (MMIP)
Ministry of Health (MOH)
Ministry of Health, Labor and Welfare (MHLW)
Ministry of Industry and Information Technology (MIIT)
Pharmaceutical and Medical Devices Agency (PMDA)
World Health Organization (WHO)
To see a report overview please e-mail Sara Peerun on firstname.lastname@example.org